Stifel Maintains Buy Rating and Lowers Price Target for ClearPoint Neuro
Stifel has maintained its "Buy" rating on ClearPoint Neuro while reducing its price target from $22 to $18.
Stocks · News reference
ClearPoint Neuro shares are trading lower after the company reported worse-than-expected Q2 financial results and cut its FY26 sales guidance below estimates.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
ClearPoint Neuro Reports Third Quarter 2026 Financial Results
ClearPoint Neuro announced its financial results for the third quarter ended September 30, 2026, reporting $12.1 million in revenue.
Crude Oil Down Over 5%; McDonald's Earnings Top Views
U.S. stocks gain with Nasdaq up more than 2% on Tuesday. Dow up 1.79% to 54,129.35, Nasdaq up 2.22% to 26,490.24, S&P 500 up 1.64% to 7,725.48. Tech shares jump 3.8%, utilities down 0.5%. McDonald's beats earnings estimates. Ibotta, Backblaze, Corvex up, Adapthealth, Better Home & Finance, Clearpoint Neuro down.
Powell Industries Posts Downbeat Q3 Results, Joins Clearpoint Neuro, Ichor Holdings And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures rise on Tuesday, but Powell Industries Inc shares fall 13.4% after reporting lower-than-expected earnings and sales.